Latest Breaking News On - Alloimmune thrombocytopenia - Page 3 : vimarsana.com

Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

  RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 Phase 1 Multiple Dose Data and Maternal-Fetal Toxicology Data On-track for 4Q 2023 Company to Host Investor and Analyst Meeting Webcast with Corresponding Slides at 4:00pm ET

Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis

Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of th

Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH   Company to Host Webcast Following ISTH Oral Presentation of RLYB212 NEW HAVEN, Conn. (BUSINESS WIRE) Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying a.